Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in J Cancer Res Clin Oncol Retrieve available abstracts of 139 articles: HTML format

Single Articles

December 2022
1. ZHU Y, Zhang Y, Hu X, Wang M, et al
   PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
   J Cancer Res Clin Oncol. 2022;148:3557-3566.
   PubMed     Abstract available
   
   
   
2. NORITAKE O, Aokage K, Suzuki A, Tane K, et al
   Prognostic impact of the number of peri-tumoral alveolar macrophages in patients with stage I lung adenocarcinoma.
   J Cancer Res Clin Oncol. 2022;148:3437-3447.
   PubMed     Abstract available
   
   
   
3. XIAO Q, Koutsilieri S, Sismanoglou DC, Lauschke VM, et al
   CFTR reduces the proliferation of lung adenocarcinoma and is a strong predictor of survival in both smokers and non-smokers.
   J Cancer Res Clin Oncol. 2022;148:3293-3302.
   PubMed     Abstract available
   
   
   November 2022
4. HAN L, Huang Z, Zhang J, Chen Y, et al
   Significance of spread through air spaces in small cell lung cancer.
   J Cancer Res Clin Oncol. 2022 Nov 22. doi: 10.1007/s00432-022-04462.
   PubMed     Abstract available
   
   
   
5. WING SE, Jankowska MM, Zou X, Sosa E, et al
   Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk.
   J Cancer Res Clin Oncol. 2022 Nov 16. pii: 10.1007/s00432-022-04455.
   PubMed     Abstract available
   
   
   
6. CHEN J, Wang D, Chen H, Gu J, et al
   TMEM196 inhibits lung cancer metastasis by regulating the Wnt/beta-catenin signaling pathway.
   J Cancer Res Clin Oncol. 2022 Nov 10. pii: 10.1007/s00432-022-04363.
   PubMed     Abstract available
   
   
   
7. LIU K, Qin Z, Ge Y, Bian A, et al
   Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study.
   J Cancer Res Clin Oncol. 2022 Nov 3. pii: 10.1007/s00432-022-04437.
   PubMed     Abstract available
   
   
   
8. YU FY, Xu Q, Wei QY, Mo HY, et al
   ACC2 is under-expressed in lung adenocarcinoma and predicts poor clinical outcomes.
   J Cancer Res Clin Oncol. 2022;148:3145-3162.
   PubMed     Abstract available
   
   
   
9. CHIANG CL, Ho HL, Yeh YC, Lee CC, et al
   Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis.
   J Cancer Res Clin Oncol. 2022 Nov 1. pii: 10.1007/s00432-022-04396.
   PubMed     Abstract available
   
   
   October 2022
10. ANDO C, Ichihara E, Yokoyama T, Inoue K, et al
    More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance.
    J Cancer Res Clin Oncol. 2022 Oct 29. pii: 10.1007/s00432-022-04415.
    PubMed     Abstract available
    
    
    
11. RAO W, Guo L, Ling Y, Dong L, et al
    Developing an effective quality evaluation strategy of next-generation sequencing for accurate detecting non-small cell lung cancer samples with variable characteristics: a real-world clinical practice.
    J Cancer Res Clin Oncol. 2022 Oct 28. pii: 10.1007/s00432-022-04388.
    PubMed     Abstract available
    
    
    
12. MA Z, Wang Z, Li Y, Zhang Y, et al
    Detection and treatment of lung adenocarcinoma at pre-/minimally invasive stage: is it lead-time bias?
    J Cancer Res Clin Oncol. 2022;148:2717-2722.
    PubMed     Abstract available
    
    
    
13. XIE J, Ruan Z, Zheng J, Gong Y, et al
    Detection of circulating rare cells benefitted the diagnosis of malignant solitary pulmonary nodules.
    J Cancer Res Clin Oncol. 2022;148:2681-2692.
    PubMed     Abstract available
    
    
    
14. WEI H, Zhou X, Yang H, Gong Y, et al
    Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.
    J Cancer Res Clin Oncol. 2022;148:2589-2598.
    PubMed     Abstract available
    
    
    September 2022
15. SHI S, Wu T, Ma Z, Zhang X, et al
    Serum-derived extracellular vesicles promote the growth and metastasis of non-small cell lung cancer by delivering the m6A methylation regulator HNRNPC through the regulation of DLGAP5.
    J Cancer Res Clin Oncol. 2022 Sep 29. pii: 10.1007/s00432-022-04375.
    PubMed     Abstract available
    
    
    
16. DENG HY, Qiu XM, Zhu DX, Tang XJ, et al
    The safety and feasibility of preoperative induction therapy of Savolitinib in non-small cell lung cancer patients with MET exon 14 skipping mutation.
    J Cancer Res Clin Oncol. 2022 Sep 28. pii: 10.1007/s00432-022-04370.
    PubMed     Abstract available
    
    
    
17. ZHANG R, Huo X, Wang Q, Zhang J, et al
    Prediction of TTF-1 expression in non-small-cell lung cancer using machine learning-based radiomics.
    J Cancer Res Clin Oncol. 2022 Sep 23. pii: 10.1007/s00432-022-04357.
    PubMed     Abstract available
    
    
    
18. KANG S, Jeong H, Park JE, Kim HS, et al
    Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis.
    J Cancer Res Clin Oncol. 2022 Sep 22. pii: 10.1007/s00432-022-04251.
    PubMed     Abstract available
    
    
    
19. LI J, Liu M, Zhang X, Ji L, et al
    Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer.
    J Cancer Res Clin Oncol. 2022 Sep 20. pii: 10.1007/s00432-022-04360.
    PubMed     Abstract available
    
    
    
20. HYUNG J, Yoon H, Choi CM, Yoon S, et al
    Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy.
    J Cancer Res Clin Oncol. 2022 Sep 5. pii: 10.1007/s00432-022-04287.
    PubMed     Abstract available
    
    
    
21. YANG Y, Xia Y, Su C, Chen J, et al
    Measuring the indirect cost associated with advanced non-small cell lung cancer: a nationwide cross-sectional study in China.
    J Cancer Res Clin Oncol. 2022 Sep 3. pii: 10.1007/s00432-022-04258.
    PubMed     Abstract available
    
    
    
22. XIE X, You M, Meng E, Wang S, et al
    Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion.
    J Cancer Res Clin Oncol. 2022;148:2561-2566.
    PubMed     Abstract available
    
    
    
23. HIZAL M, Bilgin B, Paksoy N, Atci MM, et al
    The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study).
    J Cancer Res Clin Oncol. 2022 Sep 1. pii: 10.1007/s00432-022-04252.
    PubMed     Abstract available
    
    
    
24. LAWI ZK, Al-Shuhaib MBS, Amara IB
    The rs1801280 SNP is associated with non-small cell lung carcinoma by exhibiting a highly deleterious effect on N-acetyltransferase 2.
    J Cancer Res Clin Oncol. 2022 Sep 1. pii: 10.1007/s00432-022-04332.
    PubMed     Abstract available
    
    
    August 2022
25. KANG HJ, Kwak YK, Kim M, Lee SJ, et al
    Application of real-time MRI-guided linear accelerator in stereotactic ablative body radiotherapy for non-small cell lung cancer: one step forward to precise targeting.
    J Cancer Res Clin Oncol. 2022 Aug 30. pii: 10.1007/s00432-022-04264.
    PubMed     Abstract available
    
    
    
26. WANG JL, Chen CS, Jia ZR, Miao LY, et al
    Efficacy and safety of EGFRTKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations.
    J Cancer Res Clin Oncol. 2022 Aug 26. pii: 10.1007/s00432-022-04297.
    PubMed     Abstract available
    
    
    
27. MATSUZAWA R, Morise M, Kinoshita F, Tanaka I, et al
    Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR.
    J Cancer Res Clin Oncol. 2022 Aug 25. pii: 10.1007/s00432-022-04300.
    PubMed     Abstract available
    
    
    
28. ZHANG L, Xie G, Xiao X, Cheng C, et al
    Characterization of PDL1 enhanced siRNA/albumin liposome for effective therapeutic function in lung cancer.
    J Cancer Res Clin Oncol. 2022 Aug 23. pii: 10.1007/s00432-022-04298.
    PubMed     Abstract available
    
    
    
29. HU P, Wan P, Xu A, Yan B, et al
    Neferine, a novel ROCK1-targeting inhibitor, blocks EMT process and induces apoptosis in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Aug 19. pii: 10.1007/s00432-022-04280.
    PubMed     Abstract available
    
    
    
30. WANKHEDE D, Hofman P, Grover S
    PD-1/PD-L1 inhibitors in treatment-naive, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials.
    J Cancer Res Clin Oncol. 2022 Aug 19. pii: 10.1007/s00432-022-04286.
    PubMed     Abstract available
    
    
    
31. KIM JS, Kim S, Koh J, Kim M, et al
    Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance.
    J Cancer Res Clin Oncol. 2022 Aug 17. pii: 10.1007/s00432-022-04275.
    PubMed     Abstract available
    
    
    
32. ZHANG Q, Qin S, Peng C, Liu Y, et al
    Circulating circular RNA hsa_circ_0023179 acts as a diagnostic biomarker for non-small-cell lung cancer detection.
    J Cancer Res Clin Oncol. 2022 Aug 16. pii: 10.1007/s00432-022-04254.
    PubMed     Abstract available
    
    
    
33. LIU Z, Gu X, Li Z, Shan S, et al
    Heterogeneous expression of ACE2, TMPRSS2, and FURIN at single-cell resolution in advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Aug 12. pii: 10.1007/s00432-022-04253.
    PubMed     Abstract available
    
    
    
34. LI B, Zhu T, Wu X, Chen S, et al
    The crosstalk between lung cancer cells and platelets promotes tumor angiogenesis in vivo and in vitro.
    J Cancer Res Clin Oncol. 2022 Aug 11. pii: 10.1007/s00432-022-04259.
    PubMed     Abstract available
    
    
    
35. ZHAO Y, Liu Y, Jia Y, Wang X, et al
    Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Aug 11. pii: 10.1007/s00432-022-04250.
    PubMed     Abstract available
    
    
    
36. KAPELERIS J, Muller Bark J, Ranjit S, Richard D, et al
    Modelling reoxygenation effects in non-small cell lung cancer cell lines and showing epithelial-mesenchymal transition.
    J Cancer Res Clin Oncol. 2022 Aug 6. pii: 10.1007/s00432-022-04242.
    PubMed     Abstract available
    
    
    
37. YAMADA Y, Shimada Y, Makino Y, Kudo Y, et al
    Clinical utility of psoas muscle volume in assessment of sarcopenia in patients with early-stage non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Aug 2. pii: 10.1007/s00432-022-04234.
    PubMed     Abstract available
    
    
    
38. XIE X, Chen X, Luo N, Qi Y, et al
    Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma.
    J Cancer Res Clin Oncol. 2022;148:2165-2168.
    PubMed     Abstract available
    
    
    
39. LUO YH, Liu H, Wampfler JA, Tazelaar HD, et al
    Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.
    J Cancer Res Clin Oncol. 2022;148:2099-2114.
    PubMed     Abstract available
    
    
    July 2022
40. LI S, Lu X, Zheng D, Chen W, et al
    Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression.
    J Cancer Res Clin Oncol. 2022 Jul 30. pii: 10.1007/s00432-022-04128.
    PubMed     Abstract available
    
    
    
41. FANG Y, Li Z, Chen H, Zhang T, et al
    Burden of lung cancer along with attributable risk factors in China from 1990 to 2019, and projections until 2030.
    J Cancer Res Clin Oncol. 2022 Jul 29. pii: 10.1007/s00432-022-04217.
    PubMed     Abstract available
    
    
    
42. HIGASHIYAMA RI, Horinouchi H, Kuchiba A, Matsumoto Y, et al
    Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients.
    J Cancer Res Clin Oncol. 2022 Jul 28. pii: 10.1007/s00432-022-04205.
    PubMed     Abstract available
    
    
    
43. ACHEAMPONG E, Morici M, Abed A, Bowyer S, et al
    Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2022 Jul 28. pii: 10.1007/s00432-022-04202.
    PubMed     Abstract available
    
    
    
44. TAKEUCHI E, Kondo K, Okano Y, Kunishige M, et al
    Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Jul 24. pii: 10.1007/s00432-022-04215.
    PubMed     Abstract available
    
    
    
45. INOUE Y, Inui N, Karayama M, Asada K, et al
    Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Jul 14. pii: 10.1007/s00432-022-04193.
    PubMed     Abstract available
    
    
    
46. KSIENSKI D, Gupta S, Truong PT, Bone J, et al
    Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic.
    J Cancer Res Clin Oncol. 2022 Jul 14. pii: 10.1007/s00432-022-04181.
    PubMed     Abstract available
    
    
    
47. ZHUO X, Guo H, Ma J, Lai J, et al
    Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations.
    J Cancer Res Clin Oncol. 2022 Jul 13. pii: 10.1007/s00432-022-04196.
    PubMed     Abstract available
    
    
    
48. KOWALSKI B, Valaperti A, Bezel P, Steiner UC, et al
    Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study.
    J Cancer Res Clin Oncol. 2022;148:1711-1720.
    PubMed     Abstract available
    
    
    June 2022
49. DE GIGLIO A, Deiana C, Di Federico A
    Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients.
    J Cancer Res Clin Oncol. 2022 Jun 24. pii: 10.1007/s00432-022-04120.
    PubMed     Abstract available
    
    
    
50. CHANG J, Jing X, Hua Y, Geng K, et al
    Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases.
    J Cancer Res Clin Oncol. 2022 Jun 23. pii: 10.1007/s00432-022-04121.
    PubMed     Abstract available
    
    
    
51. HATA T, Sakaguchi C, Hirano K, Kobe H, et al
    Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.
    J Cancer Res Clin Oncol. 2022 Jun 23. pii: 10.1007/s00432-022-04125.
    PubMed     Abstract available
    
    
    
52. CAI JS, Lin QY, Dou XM
    Is adjacent lobe invasion an T category upgrade factor for resected non-small cell lung cancer
    J Cancer Res Clin Oncol. 2022 Jun 21. pii: 10.1007/s00432-022-04102.
    PubMed     Abstract available
    
    
    
53. DURSLEWICZ J, Klimaszewska-Wisniewska A, Jozwicki J, Antosik P, et al
    Prognostic significance of MATR3 in stage I and II non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2022 Jun 20. pii: 10.1007/s00432-022-04097.
    PubMed     Abstract available
    
    
    
54. WANG Y, Zhang J, Hu B, Wang J, et al
    Influencing factors of lung cancer patients' participation in shared decision-making: a cross-sectional study.
    J Cancer Res Clin Oncol. 2022 Jun 18. pii: 10.1007/s00432-022-04105.
    PubMed     Abstract available
    
    
    
55. GOMPELMANN D, Sinn K, Brugger J, Bernitzky D, et al
    Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment.
    J Cancer Res Clin Oncol. 2022 Jun 16. pii: 10.1007/s00432-022-04080.
    PubMed     Abstract available
    
    
    
56. BODOR JN, Bauman JR, Handorf EA, Ross EA, et al
    Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.
    J Cancer Res Clin Oncol. 2022 Jun 16. pii: 10.1007/s00432-022-04089.
    PubMed     Abstract available
    
    
    
57. GURBUZ M, Kutlu Y, Akkus E, Koksoy EB, et al
    Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group.
    J Cancer Res Clin Oncol. 2022 Jun 11. pii: 10.1007/s00432-022-04087.
    PubMed     Abstract available
    
    
    
58. LIU C, Hu C, Chen T, Jiang Y, et al
    The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Jun 7. pii: 10.1007/s00432-022-04071.
    PubMed     Abstract available
    
    
    
59. CANAO F, Ferreira H, Neves NM
    Liposomal formulations for lung cancer treatment in the last two decades: a systematic review.
    J Cancer Res Clin Oncol. 2022 Jun 4. pii: 10.1007/s00432-022-04079.
    PubMed     Abstract available
    
    
    
60. ARNOLD S, Kortland J, Maltseva DV, Nersisyan SA, et al
    Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules, promotes pulmonary metastasis, and reduces survival in a spontaneous xenograft model of human breast cancer.
    J Cancer Res Clin Oncol. 2022;148:1525-1542.
    PubMed     Abstract available
    
    
    
61. WEN Z, Zhang Y, Fu F, Ma Z, et al
    Clinical, pathological and radiologic features of minute pulmonary meningothelial-like nodules.
    J Cancer Res Clin Oncol. 2022;148:1473-1479.
    PubMed     Abstract available
    
    
    
62. ITO M, Miyata Y, Hirano S, Irisuna F, et al
    Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2022;148:1419-1428.
    PubMed     Abstract available
    
    
    May 2022
63. CHENG ES, Weber MF, Steinberg J, Canfell K, et al
    Evaluating risk factors for lung cancer among never-smoking individuals using two Australian studies.
    J Cancer Res Clin Oncol. 2022 May 27. pii: 10.1007/s00432-022-04043.
    PubMed     Abstract available
    
    
    
64. RICCETTI N, Blettner M, Taylor K, Wehler B, et al
    Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS.
    J Cancer Res Clin Oncol. 2022 May 24. pii: 10.1007/s00432-022-03975.
    PubMed     Abstract available
    
    
    
65. LIU X, Ma C, Liu H, Sun Z, et al
    M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 May 20. pii: 10.1007/s00432-022-04032.
    PubMed     Abstract available
    
    
    
66. FAN Y, Sun R, Wang Z, Zhang Y, et al
    Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 May 18. pii: 10.1007/s00432-022-04048.
    PubMed     Abstract available
    
    
    
67. SONG J, Bai L, Zhai J, Xin Z, et al
    Allele frequency and proportion defined by circulating tumor DNA profiling predict tyrosine kinase inhibitors' therapeutic outcomes for non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 May 17. pii: 10.1007/s00432-022-03992.
    PubMed     Abstract available
    
    
    
68. ENGLMEIER F, Bleckmann A, Bruckl W, Griesinger F, et al
    Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.
    J Cancer Res Clin Oncol. 2022 May 9. pii: 10.1007/s00432-022-04034.
    PubMed     Abstract available
    
    
    
69. HAN C, Ding X, Li M, Luo N, et al
    Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.
    J Cancer Res Clin Oncol. 2022;148:1265-1268.
    PubMed     Abstract available
    
    
    
70. LI T, Fang J, Chu J, Liu X, et al
    In vivo and in vitro inhibition of SCLC by combining dual cancer-specific recombinant adenovirus with Etoposide.
    J Cancer Res Clin Oncol. 2022;148:1073-1085.
    PubMed     Abstract available
    
    
    
71. ZHANG Y, Men Y, Wang J, Xing P, et al
    Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC.
    J Cancer Res Clin Oncol. 2022;148:1137-1146.
    PubMed     Abstract available
    
    
    
72. URAMOTO H, Takiguchi T, Koizumi T, Tanimoto A, et al
    Multi-institutional survey of malignant pleural mesothelioma patients in the Hokushin region.
    J Cancer Res Clin Oncol. 2022;148:1153-1158.
    PubMed     Abstract available
    
    
    April 2022
73. HAN X, Guo J, Tang X, Zhu H, et al
    Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China.
    J Cancer Res Clin Oncol. 2022 Apr 28. pii: 10.1007/s00432-022-04023.
    PubMed     Abstract available
    
    
    
74. SHEN Y, Lu J, Hu F, Qian J, et al
    Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial.
    J Cancer Res Clin Oncol. 2022 Apr 28. pii: 10.1007/s00432-022-03964.
    PubMed     Abstract available
    
    
    
75. TANG X, Huang H, Du P, Wang L, et al
    Intratumoral and peritumoral CT-based radiomics strategy reveals distinct subtypes of non-small-cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Apr 17. pii: 10.1007/s00432-022-04015.
    PubMed     Abstract available
    
    
    
76. SHIJUBOU N, Sumi T, Yamada Y, Nakata H, et al
    Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Apr 9. pii: 10.1007/s00432-022-03941.
    PubMed     Abstract available
    
    
    
77. KUDO K, Nishii K, Makimoto G, Ishikawa N, et al
    First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.
    J Cancer Res Clin Oncol. 2022 Apr 6. pii: 10.1007/s00432-021-03893.
    PubMed     Abstract available
    
    
    
78. GURSOY P, Tatli AM, Erdem D, Goker E, et al
    Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
    J Cancer Res Clin Oncol. 2022 Apr 5. pii: 10.1007/s00432-022-03984.
    PubMed     Abstract available
    
    
    
79. XU X, Wang H, Yu Z, Chen X, et al
    A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: a case report.
    J Cancer Res Clin Oncol. 2022 Apr 2. pii: 10.1007/s00432-022-03969.
    PubMed     Abstract available
    
    
    
80. CHEN J, Yu Z, Li X, Xu G, et al
    A novel 3' truncated ALK cause ALK + in a patient with minimally invasive adenocarcinoma.
    J Cancer Res Clin Oncol. 2022;148:1005-1006.
    PubMed    
    
    
    March 2022
81. DU W, Chen C, Luo LF, He LN, et al
    Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer.
    J Cancer Res Clin Oncol. 2022 Mar 18. pii: 10.1007/s00432-022-03978.
    PubMed     Abstract available
    
    
    
82. ZHANG H, Liu M, Du G, Yu B, et al
    Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.
    J Cancer Res Clin Oncol. 2022 Mar 17. pii: 10.1007/s00432-022-03940.
    PubMed     Abstract available
    
    
    
83. PURDE MT, Niederer R, Wagner NB, Diem S, et al
    Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
    J Cancer Res Clin Oncol. 2022;148:647-656.
    PubMed     Abstract available
    
    
    
84. YAN Y, Gao Z, Han H, Zhao Y, et al
    NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2022;148:565-575.
    PubMed     Abstract available
    
    
    February 2022
85. WU G, Guo L, Gu Y, Huang T, et al
    The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients.
    J Cancer Res Clin Oncol. 2022 Feb 26. pii: 10.1007/s00432-022-03959.
    PubMed     Abstract available
    
    
    
86. ZHAO Q, Tong J, Liu X, Li S, et al
    Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: a case report.
    J Cancer Res Clin Oncol. 2022 Feb 25. pii: 10.1007/s00432-022-03931.
    PubMed     Abstract available
    
    
    
87. SUN C, Liu Y, Zhang P, Wang X, et al
    Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    J Cancer Res Clin Oncol. 2022 Feb 22. pii: 10.1007/s00432-021-03896.
    PubMed     Abstract available
    
    
    
88. LIN X, Deng H, Li S, Xie X, et al
    Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study.
    J Cancer Res Clin Oncol. 2022 Feb 10. pii: 10.1007/s00432-021-03903.
    PubMed     Abstract available
    
    
    
89. HE C, Wei C, Wen J, Chen S, et al
    Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
    J Cancer Res Clin Oncol. 2022;148:321-330.
    PubMed     Abstract available
    
    
    January 2022
90. NIEDER C, Aanes SG, Haukland E
    Primary systemic therapy for patients with brain metastases from lung cancer ineligible for targeted agents.
    J Cancer Res Clin Oncol. 2022 Jan 12. pii: 10.1007/s00432-022-03919.
    PubMed     Abstract available
    
    
    
91. CHEN Y, Jin Y, Hu X, Chen M, et al
    Infiltrating T lymphocytes in the tumor microenvironment of small cell lung cancer: a state of knowledge review.
    J Cancer Res Clin Oncol. 2022 Jan 8. pii: 10.1007/s00432-021-03895.
    PubMed     Abstract available
    
    
    
92. YU TT, Peng XC, Wang MF, Han N, et al
    Harnessing chlorin e6 loaded by functionalized iron oxide nanoparticles linked with glucose for target photodynamic therapy and improving of the immunogenicity of lung cancer.
    J Cancer Res Clin Oncol. 2022 Jan 8. pii: 10.1007/s00432-021-03879.
    PubMed     Abstract available
    
    
    
93. XU Z, Hao X, Yang K, Wang Q, et al
    Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.
    J Cancer Res Clin Oncol. 2022 Jan 4. pii: 10.1007/s00432-021-03901.
    PubMed     Abstract available
    
    
    
94. XU B, Cheng H, Li K, Lv Y, et al
    Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naive metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study.
    J Cancer Res Clin Oncol. 2022 Jan 1. pii: 10.1007/s00432-021-03873.
    PubMed     Abstract available
    
    
    December 2021
95. WANG P, Yin T, Zhao K, Yu J, et al
    Correction to: Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Dec 8. pii: 10.1007/s00432-021-03877.
    PubMed    
    
    
    
96. WEBER D, Decker M, Schuster M, Folz S, et al
    Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC.
    J Cancer Res Clin Oncol. 2021;147:3769-3771.
    PubMed     Abstract available
    
    
    
97. WU H, Zhang Y, Hu H, Li Y, et al
    Ground glass opacity featured lung adenocarcinoma in teenagers.
    J Cancer Res Clin Oncol. 2021;147:3719-3724.
    PubMed     Abstract available
    
    
    
98. NOMURA K, Aokage K, Nakai T, Sakashita S, et al
    Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2021;147:3699-3707.
    PubMed     Abstract available
    
    
    
99. UEDA D, Ito M, Tsutani Y, Gimenez-Capitan A, et al
    Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung.
    J Cancer Res Clin Oncol. 2021;147:3709-3718.
    PubMed     Abstract available
    
    
    November 2021
100. NEUMANN JM, Freitag H, Hartmann JS, Niehaus K, et al
     Subtyping non-small cell lung cancer by histology-guided spatial metabolomics.
     J Cancer Res Clin Oncol. 2021 Nov 28. pii: 10.1007/s00432-021-03834.
     PubMed     Abstract available
     
     
     
101. NAKAMURA R, Yamada T, Morimoto K, Nakao A, et al
     Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients.
     J Cancer Res Clin Oncol. 2021 Nov 26. pii: 10.1007/s00432-021-03866.
     PubMed     Abstract available
     
     
     
102. WANG P, Yin T, Zhao K, Yu J, et al
     Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2021 Nov 23. pii: 10.1007/s00432-021-03849.
     PubMed     Abstract available
     
     
     
103. CHEN Q, Li Y, Zhang W, Wang C, et al
     Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
     J Cancer Res Clin Oncol. 2021 Nov 19. pii: 10.1007/s00432-021-03858.
     PubMed     Abstract available
     
     
     
104. GAO X, Peng L, Zhang L, Huang K, et al
     Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
     J Cancer Res Clin Oncol. 2021 Nov 8. pii: 10.1007/s00432-021-03848.
     PubMed     Abstract available
     
     
     
105. FANG X, Wu G, Hua J, Zhao P, et al
     TCF-1(+) PD-1(+) CD8(+)T cells are associated with the response to PD-1 blockade in non-small cell lung cancer patients.
     J Cancer Res Clin Oncol. 2021 Nov 2. pii: 10.1007/s00432-021-03845.
     PubMed     Abstract available
     
     
     
106. UHLENBRUCH M, Kruger S
     Effect of antimicrobial therapy on progression-free survival of patients with non-small cell lung cancer receiving checkpoint inhibitor- and chemotherapy.
     J Cancer Res Clin Oncol. 2021 Nov 1. pii: 10.1007/s00432-021-03734.
     PubMed     Abstract available
     
     
     October 2021
107. BAI R, Chen X, Song W, Tian H, et al
     Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns.
     J Cancer Res Clin Oncol. 2021 Oct 26. pii: 10.1007/s00432-021-03840.
     PubMed     Abstract available
     
     
     
108. ZHOU L, Wang X, Lu J, Fu X, et al
     EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2021 Oct 18. pii: 10.1007/s00432-021-03800.
     PubMed     Abstract available
     
     
     
109. ZHAO Y, Wang H, He C
     Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
     J Cancer Res Clin Oncol. 2021 Oct 18. pii: 10.1007/s00432-021-03828.
     PubMed     Abstract available
     
     
     
110. ZENG J, Li X, Liang L, Duan H, et al
     Phosphorylation of CAP1 regulates lung cancer proliferation, migration, and invasion.
     J Cancer Res Clin Oncol. 2021 Oct 12. pii: 10.1007/s00432-021-03819.
     PubMed     Abstract available
     
     
     September 2021
111. ROCHA ALG, da Conceicao MAM, da Cunha Sequeira Mano FXP, Martins HC, et al
     Metabolic active tumour volume quantified on [(18)F]FDG PET/CT further stratifies TNM stage IV non-small cell lung cancer patients.
     J Cancer Res Clin Oncol. 2021 Sep 27. pii: 10.1007/s00432-021-03799.
     PubMed     Abstract available
     
     
     
112. TANG X, Li Y, Qian WL, Yan WF, et al
     A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.
     J Cancer Res Clin Oncol. 2021 Sep 18. pii: 10.1007/s00432-021-03797.
     PubMed     Abstract available
     
     
     
113. ZHONG Y, Wu Q, Wu S, Xie X, et al
     Comparing strategy of immune checkpoint inhibitors plus chemotherapy with chemotherapy alone for small cell lung cancer: a meta-analysis based on six RCTs incorporating 2800 participants.
     J Cancer Res Clin Oncol. 2021 Sep 17. pii: 10.1007/s00432-021-03798.
     PubMed     Abstract available
     
     
     
114. OMORI S, Muramatsu K, Kawata T, Miyawaki E, et al
     Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.
     J Cancer Res Clin Oncol. 2021 Sep 17. pii: 10.1007/s00432-021-03784.
     PubMed     Abstract available
     
     
     
115. POMPILI C, Dalmia S, McLennan Battleday F, Rogers Z, et al
     Factors influencing patient satisfaction after treatments for early-stage non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2021 Sep 13. pii: 10.1007/s00432-021-03795.
     PubMed     Abstract available
     
     
     
116. MORIMOTO K, Uchino J, Yokoi T, Kijima T, et al
     Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study.
     J Cancer Res Clin Oncol. 2021 Sep 12. pii: 10.1007/s00432-021-03782.
     PubMed     Abstract available
     
     
     
117. KASHIWABARA K, Fujii S, Tsumura S, Sakamoto K, et al
     Efficacy and safety of transbronchial microwave ablation therapy under moderate sedation in malignant central airway obstruction patients with respiratory failure: a single-institution retrospective study.
     J Cancer Res Clin Oncol. 2021;147:2751-2757.
     PubMed     Abstract available
     
     
     
118. GROGG JB, Fronzaroli JN, Oliveira P, Bode PK, et al
     Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data.
     J Cancer Res Clin Oncol. 2021;147:2671-2679.
     PubMed     Abstract available
     
     
     August 2021
119. WANG F, Jin F, Cheng B, Zhang Y, et al
     The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2021 Aug 6. pii: 10.1007/s00432-021-03752.
     PubMed     Abstract available
     
     
     
120. IANZA A, Di Chicco A, Biagi C, Giudici F, et al
     EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.
     J Cancer Res Clin Oncol. 2021;147:2301-2307.
     PubMed     Abstract available
     
     
     
121. LI P, Hou F, Wang S, Luo N, et al
     A novel NECTIN4-NTRK1 fusion identified in a lung squamous cell carcinoma patient with MSI-H.
     J Cancer Res Clin Oncol. 2021;147:2483-2486.
     PubMed    
     
     
     July 2021
122. HIZAL M, Bilgin B, Paksoy N, Acikgoz O, et al
     The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.
     J Cancer Res Clin Oncol. 2021 Jul 31. pii: 10.1007/s00432-021-03748.
     PubMed     Abstract available
     
     
     
123. YANG Z, Yu R, Deng W, Wang W, et al
     Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer.
     J Cancer Res Clin Oncol. 2021 Jul 29. pii: 10.1007/s00432-021-03740.
     PubMed     Abstract available
     
     
     
124. SU Z, Jiang Y, Li C, Zhong R, et al
     Relationship between lung function and lung cancer risk: a pooled analysis of cohorts plus Mendelian randomization study.
     J Cancer Res Clin Oncol. 2021 Jul 27. pii: 10.1007/s00432-021-03619.
     PubMed     Abstract available
     
     
     
125. OTA T, Kirita K, Matsuzawa R, Udagawa H, et al
     Correction to: Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified.
     J Cancer Res Clin Oncol. 2021 Jul 23. pii: 10.1007/s00432-021-03737.
     PubMed    
     
     
     
126. SUN J, Zhang J, Hu H, Qin H, et al
     Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer.
     J Cancer Res Clin Oncol. 2021 Jul 21. pii: 10.1007/s00432-021-03735.
     PubMed     Abstract available
     
     
     
127. BRANCHER S, Ribeiro AE, Toporcov TN, Weiderpass E, et al
     The role of metformin on lung cancer survival: the first systematic review and meta-analysis of observational studies and randomized clinical trials.
     J Cancer Res Clin Oncol. 2021 Jul 15. pii: 10.1007/s00432-021-03728.
     PubMed     Abstract available
     
     
     
128. GUO R, Zhang Y, Ma Z, Deng C, et al
     Overuse of follow-up chest computed tomography in patients with incidentally identified nodules suspicious for lung cancer.
     J Cancer Res Clin Oncol. 2021 Jul 8. pii: 10.1007/s00432-021-03692.
     PubMed     Abstract available
     
     
     
129. HE X, Ma X, Wang C, Luan M, et al
     The peptide mimicking small extracellular ring domain of CD82 inhibits tumor cell migration in vitro and metastasis in vivo.
     J Cancer Res Clin Oncol. 2021;147:1927-1934.
     PubMed     Abstract available
     
     
     
130. LIU J, Hao J, Niu Y, Wu X, et al
     Network pharmacology-based and clinically relevant prediction of active ingredients and potential targets of Chinese herbs on stage IV lung adenocarcinoma patients.
     J Cancer Res Clin Oncol. 2021;147:2079-2092.
     PubMed     Abstract available
     
     
     June 2021
131. DOU Y, Duan Q, Qi C, Hou L, et al
     An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2021;147:1865-1867.
     PubMed     Abstract available
     
     
     May 2021
132. SHEN Z, Chen C, Sun J, Huang J, et al
     The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer.
     J Cancer Res Clin Oncol. 2021 May 26. pii: 10.1007/s00432-021-03640.
     PubMed     Abstract available
     
     
     
133. ZHANG Y, Zhang Z, Ding Y, Fang Y, et al
     Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.
     J Cancer Res Clin Oncol. 2021 May 25. pii: 10.1007/s00432-021-03613.
     PubMed     Abstract available
     
     
     
134. ZHAO Y, Liu Y, Li S, Peng Z, et al
     Role of lung and gut microbiota on lung cancer pathogenesis.
     J Cancer Res Clin Oncol. 2021 May 20. pii: 10.1007/s00432-021-03644.
     PubMed     Abstract available
     
     
     
135. DAI Y, Zhong F, Liu W, Song Q, et al
     Mycoplasma hyorhinis infection promotes tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients.
     J Cancer Res Clin Oncol. 2021;147:1379-1388.
     PubMed     Abstract available
     
     
     
136. FRANZESE C, Badalamenti M, Teriaca A, De Virgilio A, et al
     Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
     J Cancer Res Clin Oncol. 2021;147:1307-1313.
     PubMed     Abstract available
     
     
     April 2021
137. LEONETTI A, Carbone D, Gregori A, Tiseo M, et al
     A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?
     J Cancer Res Clin Oncol. 2021 Apr 26. pii: 10.1007/s00432-021-03647.
     PubMed    
     
     
     
138. QIU X, Zhang H, Zhao Y, Zhao J, et al
     Application of circulating genetically abnormal cells in the diagnosis of early-stage lung cancer.
     J Cancer Res Clin Oncol. 2021 Apr 24. pii: 10.1007/s00432-021-03648.
     PubMed     Abstract available
     
     
     
139. NOUNU A, Walker V, Richmond RC
     Correction to: Letter regarding, "Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses".
     J Cancer Res Clin Oncol. 2021 Apr 11. pii: 10.1007/s00432-021-03636.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: